Ceapro Logo.jpg
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
09 nov. 2022 09h00 HE | Ceapro Inc.
– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology – Q3 2022 sales of $3,845,000 vs $4,523,000 in Q3 2021; YTD sales...
Ceapro Logo.jpg
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
07 nov. 2022 09h00 HE | Ceapro Inc.
PGX processing unit to be installed at Agri-Food Discovery Place of University of AlbertaAlginate and yeast beta glucan to be the first bio actives to be processed at this location EDMONTON,...
Ceapro Logo.jpg
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
13 oct. 2022 08h35 HE | Ceapro Inc.
Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a...
Ceapro Logo.jpg
Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
24 août 2022 09h00 HE | Ceapro Inc.
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income...
Ceapro Logo.jpg
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis
11 août 2022 09h05 HE | Ceapro Inc.
– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the...
Ceapro Logo.jpg
Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer
12 juil. 2022 08h35 HE | Ceapro Inc.
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta,...
Ceapro Logo.jpg
Ceapro Announces Results of 2022 Shareholders’ Meeting
07 juin 2022 08h05 HE | Ceapro Inc.
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
23 mai 2022 09h00 HE | Ceapro Inc.
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Logo.jpg
Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update
18 mai 2022 09h00 HE | Ceapro Inc.
– Best quarterly financial results in history of the Company – Q1 2022 sales of $6,172,000 vs $4,702,000 in Q1 2021, a 31% increase – Operating profit of $2,614,000 in Q1 2022 vs $515,000 in Q1...
Ceapro Logo.jpg
Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
13 mai 2022 09h00 HE | Ceapro Inc.
EDMONTON, Alberta, May 13, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...